Airway Therapeutics is pioneering a new class of biologics aimed at addressing respiratory and inflammatory diseases, particularly focusing on bronchopulmonary dysplasia (BPD) in preterm infants. Their lead product, zelpultide alfa (AT-100), is a novel recombinant human protein engineered from the endogenous protein hSP-D. This biologic is designed to reduce inflammation and infection while modulating the immune response, effectively breaking the cycle of injury and inflammation that characterizes conditions like BPD. The company emphasizes the critical roles of AT-100 in maintaining lung health, including its anti-inflammatory properties, its ability to clear pathogens, and its regulation of lipid homeostasis in the lungs.

AT-100 has shown promise in various applications beyond BPD, including severe COVID-19 and other respiratory infections such as influenza and respiratory syncytial virus (RSV). The protein's mechanism involves binding to pathogens, inhibiting their replication, and enhancing their clearance by lung immune cells, thereby mitigating the inflammatory responses that can lead to further lung damage. Airway Therapeutics has received orphan drug designation for AT-100 in the prevention of BPD, reflecting its potential to fill a significant unmet medical need. The company is advancing its clinical programs with favorable feedback from regulatory authorities, indicating a strong pathway toward further development and potential commercialization.

United States

Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics.  Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.

Airway Therapeutics

Company Details